NCT04002284 is a Phase 2 clinical trial of Anlotinib Hydrochloride in Breast Neoplasm, sponsored by Peng Yuan.

Who is sponsoring NCT04002284?

NCT04002284 is sponsored by Peng Yuan.

What drugs are being tested in NCT04002284?

Interventions in NCT04002284: Anlotinib Hydrochloride.

What condition does NCT04002284 study?

NCT04002284 studies Breast Neoplasm, Antineoplastic Agents, Anlotinib.

Is NCT04002284 still recruiting?

NCT04002284 is currently completed. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT04002284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib in Metastatic HER2 Negative Breast Cancer

Completed Phase 2 Last updated 29 July 2020

What this trial tests

Phase 2 trial testing Anlotinib Hydrochloride in Breast Neoplasm in 26 participants. Completed in 15 March 2020.

Timeline

12 July 2018

Primary endpoint
10 January 2020

15 March 2020

Quick facts

Lead sponsor	Peng Yuan
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	12 July 2018
Primary completion	10 January 2020
Estimated completion	15 March 2020
Sites	1 location across China

Drugs / interventions tested

Anlotinib Hydrochloride

Conditions studied

Breast Neoplasm — all drugs for Breast Neoplasm →
Antineoplastic Agents — all drugs for Antineoplastic Agents →
Anlotinib — all drugs for Anlotinib →

Sponsor

Peng Yuan — full company profile →

Who can join

Adults 18 to 75, female only, with Breast Neoplasm or Antineoplastic Agents. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.
Hu N, Si Y, Yue J, Sun T, et al · · 2021 · cited 33× · PMID 33710812 · DOI 10.20892/j.issn.2095-3941.2020.0463
REThinking the role of the RET oncogene in breast cancer.
Di Grazia G, Conti C, Nucera S, Motta G, et al · · 2024 · cited 1× · PMID 39211557 · DOI 10.3389/fonc.2024.1427228

Verify or expand the search:

Other trials of Anlotinib Hydrochloride

Trials testing the same drug.

NCT05485350 — Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · unknown
NCT04959500 — Newly Diagnosed Glioblastoma · Phase 2 · active not recruiting
NCT05035914 — Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer · Phase 1, PHASE2 · unknown
NCT04080843 — Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients · Phase 2 · completed
NCT04111913 — A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small · Phase 2 · unknown

Other recruiting trials for Breast Neoplasm

Currently open trials in the same condition.

NCT07054723 — Surviving Daily Life · recruiting
NCT06839001 — CRYoablation for Small Tumors As Local Treatment - SIX Trial · Phase 3 · recruiting
NCT06672302 — A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify · recruiting
NCT06255808 — Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor · active not recruiting
NCT06622967 — KNUCH CadAI-B-1(KCB-1) · NA · active not recruiting

Other Peng Yuan trials

Trials by the same sponsor.

NCT07046780 — A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in th · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04002284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peng Yuan
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04002284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing